zurück

Lorlatinib (new indication: non-small cell lung cancer (NSCLC), ALK+ mutation, 1st line)

Subject:

  • Active Substance: Lorlatinib
  • Name: Lorviqua®
  • Therapeutic area: Non-small cell lung cancer (NSCLC)
  • Pharmaceutical company: Pfizer Pharma GmbH

Time table:

  • Start: 01.03.2022
  • Final decision by G-BA: 01.09.2022

Final decision:

  • No additional benefit proved